Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 4, 2013, Pages 895-899

  Sauermann, Robert ^a   Burian, Bernhard ^a   Burian, Angela ^a   Jäger, Walter ^b   Höferl, Martina ^b   Stella, Alexander ^c   Theurer, Stefanie ^a   Riedl, Michaela ^a   Zeitlinger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Diabetes mellitus; Inflamed tissue; Microdialysis; Target site concentrations

Indexed keywords

ERTAPENEM;

ADULT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BLOOD ANALYSIS; CLINICAL ARTICLE; DIABETIC FOOT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; INTERSTITIUM; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; STEADY STATE; SUBCUTANEOUS FAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; DIABETIC FOOT; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA; SKIN; YOUNG ADULT;

EID: 84875239183     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks479     Document Type: Article

References (29)

1. Seaton RA, Sharp E, Bezlyak V et al. Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int J Antimicrob Agents 2011; 38: 243-8.
2. Kosinski MA, Lipsky BA. Current medical management of diabetic foot infections. Expert Rev Anti Infect Ther 2010; 8: 1293-305.
3. Mendes JJ, Marques-Costa A, Vilela C et al. Clinical and bacteriological survey of diabetic foot infections in Lisbon. Diabetes Res Clin Pract 2012; 95: 153-61.
4. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005; 65: 2151-78.
5. Burkhardt O, Brunner M, Schmidt S et al. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother 2006; 58: 632-6.
6. Joukhadar C, Dehghanyar P, Traunmuller F et al. Increase of microcirculatory blood flow enhances penetration of ciprofloxacin into soft tissue. Antimicrob Agents Chemother 2005; 49: 4149-53.
7. Joukhadar C, Klein N, Frossard M et al. Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. Clin Pharmacol Ther 2001; 70: 532-9.
8. Muller M, Brunner M, Hollenstein U et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother 1999; 43: 2056-8.
9. Sauermann R, Mayer-Helm BX, Petsch M et al. Is experimental endotoxaemia in humans suitable for simulating antibiotic pharmacokinetics in sepsis and septic shock? A pilot study using the model compound fosfomycin. Int J Antimicrob Agents 2008; 31: 291-2.
10. Thallinger C, Buerger C, Plock N et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008; 61: 173-6.
11. Lonnroth P, Jansson PA, Smith U. A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol 1987; 253: 228-31.
12. Muller M, Haag O, Burgdorff T et al. Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob Agents Chemother 1996; 40: 2703-9.
13. Muller M, Schmid R, Georgopoulos A et al. Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 1995; 57: 371-80.
14. Muller M. Microdialysis in clinical drug delivery studies. Adv Drug Deliv Rev 2000; 45: 255-69.
15. Sauermann R, Delle-Karth G, Marsik C et al. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother 2005; 49: 650-5.
16. Majumdar AK, Musson DG, Birk KL et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-11.
17. Brink AJ, Richards GA, Schillack V et al. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents 2009; 33: 432-6.
18. Burkhardt O, Kumar V, Katterwe D et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007; 59: 277-84.
19. Ulldemolins M, Roberts JA, Rello J et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50: 99-110.
20. Legat FJ, Maier A, Dittrich P et al. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother 2003; 47: 371-4.
21. Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004; 53 SUPPL 2: ii11-21.
22. Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45: 1915-8.
23. Loza E, Morosini MI, Cantón R et al. Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria. Rev Esp Quimioter 2003; 16: 209-15.
24. Goldstein EJ, Citron DM, Merriam CV et al. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob Agents Chemother 2008; 52: 761-6.
25. Fuchs PC, Barry AL, Brown SD. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. J Antimicrob Chemother 2001; 48: 557-61.
26. Citron DM, Goldstein EJ, Merriam CV et al. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007; 45: 2819-28.
27. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
28. Burkhardt O, Kumar V, Schmid S et al. Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. Int J Antimicrob Agents 2010; 35: 96-7.
29. Boyadjiev I, Boulamery A, Simon N et al. Penetration of ertapenem into muscle measured by in vivo microdialysis in mechanically ventilated patients. Antimicrob Agents Chemother 2011; 55: 3573-5.